TABLE OF CONTENTS
1 INTRODUCTION 75
1.1 OBJECTIVES OF THE STUDY 75
1.2 MARKET DEFINITION 75
1.3 OVERVIEW OF THE EUROPE FECAL OCCULT BLOOD TESTS MARKET 75
1.4 CURRENCY AND PRICING 77
1.5 LIMITATIONS 77
1.6 MARKETS COVERED 77
2 MARKET SEGMENTATION 81
2.1 MARKETS COVERED 81
2.2 GEOGRAPHICAL SCOPE 82
2.3 YEARS CONSIDERED FOR THE STUDY 83
2.4 DBMR TRIPOD DATA VALIDATION MODEL 84
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 87
2.6 MULTIVARIATE MODELLING 88
2.7 PRODUCT TYPE SEGMENT LIFELINE CURVE 88
2.8 MARKET APPLICATION COVERAGE GRID 89
2.9 DBMR MARKET POSITION GRID 90
2.10 VENDOR SHARE ANALYSIS 91
2.11 SECONDARY SOURCES 92
2.12 ASSUMPTIONS 92
3 EXECUTIVE SUMMARY 93
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTER'S 5 FORCES 97
5 INDUSTRY INSIGHTS 98
6 REGULATORY FRAMEWORK 100
6.1 REGULATORY SCENARIO BY U.S. FDA 100
6.2 REGULATORY SCENARIO IN U.S. 100
6.3 REGULATORY SCENARIO IN EUROPE 101
6.4 REGULATORY SCENARIO IN CANADA 101
6.5 REGULATORY SCENARIO IN AUSTRALIA 101
7 MARKET OVERVIEW 102
7.1 DRIVERS 104
7.1.1 RISING CASES OF COLORECTAL CANCER EUROPELY 104
7.1.2 DEVELOPMENT OF DIRECT-TO-CONSUMER LABORATORY TESTING 104
7.1.3 EASY AVAILABILITY OF FECAL OCCULT IMMUNOLOGICAL TEST DEVICES IN ONLINE STORES 105
7.1.4 INCREASING INCLINATION TOWARDS POINT-OF-CARE DIAGNOSTICS 105
7.2 RESTRAINTS 105
7.2.1 CHANGE IN CONSUMER PREFERENCE TOWARDS COST-EFFECTIVE ALTERNATIVES 105
7.2.2 LOW AWARENESS ABOUT FECAL OCCULT BLOOD TESTS IN UNDEVELOPED COUNTRIES 106
7.3 OPPORTUNITIES 106
7.3.1 INCREASE IN SCREENING PROCEDURES 106
7.3.2 RISING TECHNICAL ADVANCEMENTS 107
7.3.3 STRATEGIC INITIATIVES 107
7.4 CHALLENGES 108
7.4.1 LACK OF SKILLED PROFESSIONALS 108
7.4.2 LOW EFFICIENCY 108
8 EUROPE FECAL OCCULT BLOOD TESTS MARKET, BY TEST TYPE 109
8.1 OVERVIEW 110
8.2 LATERAL FLOW IMMUNO-FOB TEST KITS 113
8.3 IMMUNO-FOB AGGLUTINATION TEST KITS 113
8.4 IMMUNO-FOB ELISA TEST KITS 114
8.5 GUAIAC FOB STOOL TEST 115
8.5.1 KITS 116
8.5.1.1 GUAIAC SLIDES 116
8.5.1.1.1 25 PACKAGE 116
8.5.1.1.2 20 PACKAGE 116
8.5.1.1.3 OTHERS 116
8.5.1.2 ALPHA GUAIACONIC ACID (GUAIAC) IMPREGNATED PAPER 117
8.5.1.2.1 SENSITIVITY IS 50NG/ML 117
8.5.1.2.1.1 25 PACKAGE 117
8.5.1.2.1.2 20 PACKAGE 117
8.5.1.2.1.3 OTHERS 118
8.5.1.2.2 SENSITIVITY IS 75NG/ML 118
8.5.1.2.2.1 25 PACKAGE 118
8.5.1.2.2.2 20 PACKAGE 118
8.5.1.2.2.3 OTHERS 118
8.5.1.2.3 OTHERS 118
8.5.1.3 OTHERS 119
8.5.2 REAGENTS 119
8.5.2.1 HYDROGEN PEROXIDE 119
8.5.2.2 OTHERS 119
8.6 FLUSHABLE REAGENT PAD OR TISSUE 119
8.7 OTHERS 120
9 EUROPE FECAL OCCULT BLOOD TESTS MARKET, BY APPLICATION 121
9.1 OVERVIEW 122
9.2 COLORECTAL CANCER SCREENING 125
9.2.1 LATERAL FLOW IMMUNO-FOB TEST KITS 126
9.2.2 IMMUNO-FOB AGGLUTINATION TEST KITS 126
9.2.3 IMMUNO-FOB ELISA TEST KITS 126
9.2.4 GUAIAC FOB STOOL TEST 126
9.2.5 FLUSHABLE REAGENT PAD OR TISSUE 126
9.2.6 OTHERS 126
9.3 CONCERN FOR GASTROINTESTINAL BLEEDING 126
9.3.1 LATERAL FLOW IMMUNO-FOB TEST KITS 127
9.3.2 IMMUNO-FOB AGGLUTINATION TEST KITS 127
9.3.3 IMMUNO-FOB ELISA TEST KITS 127
9.3.4 GUAIAC FOB STOOL TEST 128
9.3.5 FLUSHABLE REAGENT PAD OR TISSUE 128
9.3.6 OTHERS 128
9.4 POLYPS 128
9.4.1 LATERAL FLOW IMMUNO-FOB TEST KITS 129
9.4.2 IMMUNO-FOB AGGLUTINATION TEST KITS 129
9.4.3 IMMUNO-FOB ELISA TEST KITS 129
9.4.4 GUAIAC FOB STOOL TEST 129
9.4.5 FLUSHABLE REAGENT PAD OR TISSUE 129
9.4.6 OTHERS 129
9.5 DIVERTICULOSIS 130
9.5.1 LATERAL FLOW IMMUNO-FOB TEST KITS 131
9.5.2 IMMUNO-FOB AGGLUTINATION TEST KITS 131
9.5.3 IMMUNO-FOB ELISA TEST KITS 131
9.5.4 GUAIAC FOB STOOL TEST 131
9.5.5 FLUSHABLE REAGENT PAD OR TISSUE 131
9.5.6 OTHERS 131
9.6 ULCERS 131
9.6.1 LATERAL FLOW IMMUNO-FOB TEST KITS 132
9.6.2 IMMUNO-FOB AGGLUTINATION TEST KITS 132
9.6.3 IMMUNO-FOB ELISA TEST KITS 132
9.6.4 GUAIAC FOB STOOL TEST 133
9.6.5 FLUSHABLE REAGENT PAD OR TISSUE 133
9.6.6 OTHERS 133
9.7 HAEMORRHOIDS 133
9.7.1 LATERAL FLOW IMMUNO-FOB TEST KITS 134
9.7.2 IMMUNO-FOB AGGLUTINATION TEST KITS 134
9.7.3 IMMUNO-FOB ELISA TEST KITS 134
9.7.4 GUAIAC FOB STOOL TEST 134
9.7.5 FLUSHABLE REAGENT PAD OR TISSUE 134
9.7.6 OTHERS 134
9.8 COLITIS 135
9.8.1 LATERAL FLOW IMMUNO-FOB TEST KITS 136
9.8.2 IMMUNO-FOB AGGLUTINATION TEST KITS 136
9.8.3 IMMUNO-FOB ELISA TEST KITS 136
9.8.4 GUAIAC FOB STOOL TEST 136
9.8.5 FLUSHABLE REAGENT PAD OR TISSUE 136
9.8.6 OTHERS 136
9.9 ANEMIA 136
9.9.1 LATERAL FLOW IMMUNO-FOB TEST KITS 137
9.9.2 IMMUNO-FOB AGGLUTINATION TEST KITS 137
9.9.3 IMMUNO-FOB ELISA TEST KITS 137
9.9.4 GUAIAC FOB STOOL TEST 138
9.9.5 FLUSHABLE REAGENT PAD OR TISSUE 138
9.9.6 OTHERS 138
9.10 OTHERS 138
10 EUROPE FECAL OCCULT BLOOD TESTS MARKET, BY END USER 139
10.1 OVERVIEW 140
10.2 DIAGNOSTIC LABORATORIES 143
10.3 HOSPITALS 143
10.4 SPECIALITY CLINICS 144
10.5 OTHERS 145
11 EUROPE FECAL OCCULT BLOOD TESTS MARKET, BY DISTRIBUTION CHANNEL 146
11.1 OVERVIEW 147
11.2 DIRECT TENDER 150
11.3 RETAIL SALE 150
11.4 E-COMMERCE 151
11.5 OTHERS 152
12 EUROPE FECAL OCCULT BLOOD TESTS MARKET, BY REGION 153
12.1 EUROPE 154
12.1.1 GERMANY 169
12.1.2 FRANCE 179
12.1.3 U.K. 189
12.1.4 ITALY 199
12.1.5 SPAIN 209
12.1.6 RUSSIA 219
12.1.7 SWITZERLAND 229
12.1.8 NETHERLANDS 239
12.1.9 TURKEY 249
12.1.10 BELGIUM 259
12.1.11 REST OF EUROPE 269
13 EUROPE FECAL OCCULT BLOOD TESTS MARKET: COMPANY LANDSCAPE 270
13.1 COMPANY SHARE ANALYSIS: EUROPE 270
14 SWOT ANALYSIS 271
15 COMPANY PROFILE 272
15.1 QUIDEL CORPORATION 272
15.1.1 COMPANY SNAPSHOT 272
15.1.2 REVENUE ANALYSIS 272
15.1.3 COMPANY SHARE ANALYSIS 273
15.1.4 PRODUCT PORTFOLIO 273
15.1.5 RECENT DEVELOPMENT 273
15.2 WONDFO. 274
15.2.1 COMPANY SNAPSHOT 274
15.2.2 COMPANY SHARE ANALYSIS 274
15.2.3 PRODUCT PORTFOLIO 275
15.2.4 RECENT DEVELOPMENT 275
15.3 SIEMENS HEALTHCARE GMBH 276
15.3.1 COMPANY SNAPSHOT 276
15.3.2 REVENUE ANALYSIS 276
15.3.3 COMPANY SHARE ANALYSIS 277
15.3.4 RODUCT PORTFOLIO 277
15.3.5 RECENT DEVELOPMENT 277
15.4 EIKEN CHEMICAL CO., LTD. 278
15.4.1 COMPANY SNAPSHOT 278
15.4.2 REVENUE ANALYSIS 278
15.4.3 COMPANY SHARE ANALYSIS 279
15.4.4 PRODUCT PORTFOLIO 279
15.4.5 RECENT DEVELOPMENT 279
15.5 BIOHIT OYJ 280
15.5.1 COMPANY SNAPSHOT 280
15.5.2 REVENUE ANALYSIS 280
15.5.3 COMPANY SHARE ANALYSIS 281
15.5.4 PRODUCT PORTFOLIO 281
15.5.5 RECENT DEVELOPMENT 281
15.6 ACCUBIOTECH CO LTD 282
15.6.1 COMPANY SNAPSHOT 282
15.6.2 PRODUCT PORTFOLIO 282
15.6.3 RECENT DEVELOPMENT 282
15.7 ACCUQUIK TEST KITS 283
15.7.1 COMPANY SNAPSHOT 283
15.7.2 PRODUCT PORTFOLIO 283
15.7.3 RECENT DEVELOPMENT 283
15.8 AIDIAN 284
15.8.1 COMPANY PROFILE 284
15.8.2 PRODUCT PORTFOLIO 284
15.8.3 RECENT DEVELOPMENT 284
15.9 ALFA SCIENTIFIC DESIGNS, INC. 285
15.9.1 COMPANY SNAPSHOT 285
15.9.2 PRODUCT PORTFOLIO 285
15.9.3 RECENT DEVELOPMENT 285
15.10 APACOR LIMITED 286
15.10.1 COMPANY SNAPSHOT 286
15.10.2 PRODUCT PORTFOLIO 286
15.10.3 RECENT DEVELOPMENT 286
15.11 BIOPANDA REAGENTS LTD 287
15.11.1 COMPANY SNAPSHOT 287
15.11.2 PRODUCT PORTFOLIO 287
15.11.3 RECENT DEVELOPMENT 287
15.12 BODITECH MED INC. 288
15.12.1 COMPANY SNAPSHOT 288
15.12.2 PRODUCT PORTFOLIO 288
15.12.3 RECENT DEVELOPMENT 288
15.13 CENOGENICS CORPORATION 289
15.13.1 COMPANY SNAPSHOT 289
15.13.2 PRODUCT PORTFOLIO 289
15.13.3 RECENT DEVELOPMENT 289
15.14 CERTEST BIOTEC. 290
15.14.1 COMPANY SNAPSHOT 290
15.14.2 PRODUCT PORTFOLIO 290
15.14.3 RECENT DEVELOPMENT 290
15.15 CTK BIOTECH, INC. 291
15.15.1 COMPANY SNAPSHOT 291
15.15.2 PRODUCT PORTFOLIO 291
15.15.3 RECENT DEVELOPMENT 291
15.16 EDP BIOTECH 292
15.16.1 COMPANY SNAPSHOT 292
15.16.2 PRODUCT PORTFOLIO 292
15.16.3 1.16.3 RECENT DEVELOPMENT 292
15.17 EPITOPE DIAGNOSTICS, INC. 293
15.17.1 COMPANY SNAPSHOT 293
15.17.2 PRODUCT PORTFOLIO 293
15.17.3 RECENT DEVELOPMENT 293
15.18 EUROLYSER DIAGNOSTICA GMBH 294
15.18.1 COMPANY SNAPSHOT 294
15.18.2 PRODUCT PORTFOLIO 294
15.18.3 RECENT DEVELOPMENT 294
15.19 FIRSTEP 295
15.19.1 COMPANY SNAPSHOT 295
15.19.2 PRODUCT PORTFOLIO 295
15.19.3 RECENT DEVELOPMENT 295
15.20 HANGZHOU CLONGENE BIOTECH CO., LTD 296
15.20.1 COMPANY SNAPSHOT 296
15.20.2 PRODUCT PORTFOLIO 296
15.20.3 RECENT DEVELOPMENT 296

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.